COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer

Andresciani, Flavio; Ricci, Milena; Grasso, Rosario Francesco; Zobel, Bruno Beomonte; Quattrocchi, Carlo Cosimo

doi:10.1016/j.radcr.2022.05.072

Cited by 7 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postvaccination lymph node uptake on 18 F-FDG PET has been demonstrated in prior case reports or case series on COVID-19 and flu vaccine for a variety of tumor entities ( 1 – 4 , 11 – 16 ). An increase in annual vaccination will put oncologic patients at considerable risk of false-positive 18 F-FDG PET findings.…”

Section: Discussionmentioning

confidence: 75%

Novel⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Demmert

Maríc

Pomykala³

et al. 2022

J Nucl Med

View full text Add to dashboard Cite

In the setting of ongoing COVID-19 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by 18 F-FDG PET/CT. 68 Ga-FAPI PET/CT is a new oncologic imaging tool that may overcome this limitation.Methods: We assessed post-vaccine, head-to-head and same-day 18 F-FDG and 68 Ga-FAPI-46 PET/CT findings in a series of 11 patients from a large prospective imaging registry. All patients with documented tracer uptake in locoregional lymph nodes on PET/CT or PET/MRI, following vaccination within 6 weeks, were eligible for investigation.Result: Significant visual lymph node uptake adjacent to the injection site was noted in 11/11 (100%) patients with 18 F-FDG PET/CT versus 0/11 (0%) with 68 Ga-FAPI PET/CT. 18 F-FDG detected 73% and 68 Ga-FAPI PET/CT 94% of all tumor lesions. Conclusion:In this case-series study, 68 Ga-FAPI showed its potential to avoid 18 F-FDG-PET/CT post-vaccination pitfalls and presented superior tumor localization.Squibb, Celgene, Eisbach Bio, Roche/Genentech; he holds ownership and serves on the Board of Directors of Pharma15, all outside the submitted work.Benedikt M. Schaarschmidt received a research grant from PharmaCept for an undergoing investigator-initiated study not related to this paper.

show abstract

Section: Discussionmentioning

confidence: 75%

Novel⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Demmert

Maríc

Pomykala³

et al. 2022

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Several reports of case series and case reports indicated the association of inflammation and KD with C19-VAL development [ 24 , 36 , 38 , 39 , 40 , 79 , 80 , 81 , 82 , 83 ]. Some of the studies indicated that the inflammation of C19-VAL shows the abundant inflammatory cells in the biopsy [ 24 , 36 ] or high choline uptake in the imaging of LN [ 79 ]. Four case reports found C19-VAL with necrotizing lymphadenitis in LN biopsy, which were diagnosed as KD [ 39 , 40 , 81 , 82 ].…”

Section: Resultsmentioning

confidence: 99%

Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination

Shen

Chang

et al. 2023

Vaccines

View full text Add to dashboard Cite

Mass vaccination against coronavirus disease 2019 (COVID-19) is a global health strategy to control the COVID-19 pandemic. With the increasing number of vaccinations, COVID-19 vaccine-associated lymphadenopathy (C19-VAL) has been frequently reported. Current findings emphasize the characteristics of C19-VAL. The mechanism of C19-VAL is complicated to explore. Accumulated reports separately show that C19-VAL incidence is associated with receiver age and gender, reactive change within lymph nodes (LN), etc. We constructed a systematic review to evaluate the associated elements of C19-VAL and provide the mechanism of C19-VAL. Articles were searched from PubMed, Web of Science and EMBASE by using the processing of PRISMA. The search terms included combinations of the COVID-19 vaccine, COVID-19 vaccination and lymphadenopathy. Finally, sixty-two articles have been included in this study. Our results show that days post-vaccination and B cell germinal center response are negatively correlated with C19-VAL incidence. The reactive change within LN is highly related to C19-VAL development. The study results suggested that strong vaccine immune response may contribute to the C19-VAL development and perhaps through the B cell germinal center response post vaccination. From the perspective of imaging interpretation, it is important to carefully distinguish reactive lymph nodes from metastatic lymph node enlargement through medical history collection or evaluation, especially in patients with underlying malignancy.

show abstract

“…Recently, Andresciani et al (7) reported a 62-year-old man with bone-metastatic prostate cancer with lymph node involvement. The patients received hormone therapy and radiotherapy.…”

Section: Paraclinical Findings After Injection Of Covid-19 Vaccine In...mentioning

confidence: 99%

Cancer recurrence or aggravation following COVID-19 vaccination

Soleimani¹,

Yadollahifarsani²,

Motieian³

et al. 2023

J Nephropharmacol

View full text Add to dashboard Cite

COVID-19 infection has been a global health issue in the past recent years and numerous topics are studied in order to discover its pathophysiology and potential side effects. The potential for disease recurrence following the administration of the COVID-19 vaccine is one of the issues that has recently attracted attention. Several studies have revealed that the COVID-19 vaccines, like other vaccines, may have side effects and, in some cases, they may even deteriorate the underlying illnesses, such as rheumatic diseases, autoimmune diseases, and cancers. The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine. Lymph node involvement, disease recurrence, and potential paraclinical changes after receiving the COVID-19 vaccine are some of the concerns of patients with malignancy. In this mini-review, we attempted to investigate cases of cancer recurrence or recovery as well as lymphadenopathy following vaccination.

show abstract

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer

Cited by 7 publications

References 16 publications

Novel⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Novel⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination

Cancer recurrence or aggravation following COVID-19 vaccination

Contact Info

Product

Resources

About

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer

Cited by 7 publications

References 16 publications

Novel68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Novel68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination

Cancer recurrence or aggravation following COVID-19 vaccination

Contact Info

Product

Resources

About

Novel⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls

Novel⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls